Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 10/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.39 |
| ▸ | USP5 | P45974 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 2/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | ADAMTS7 | Q9UKP4 | 1/20 | 0.36 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4842584 | 0.93 | MRGPRX4 (0.40) | RORCMRGPRX4USP5KIFC1 | |
| SCHEMBL4839389 | 0.92 | RORC (0.39) | RORCUSP5MMP8MMP3ADAMTS7 | |
| SCHEMBL4840586 | 0.92 | RORC (0.40) | RORCUSP5MMP8MMP3ADAMTS7 | |
| SCHEMBL4845108 | 0.92 | RORC (0.39) | RORCMRGPRX4MMP8MMP3ADAMTS7 | |
| SCHEMBL4845413 | 0.91 | PPARD (0.42) | RORCMMP8MMP3PPARD | |
| SCHEMBL4840319 | 0.89 | RORC (0.43) | RORCMMP8MMP3ADAMTS7ADAMTS5 | |
| SCHEMBL4840605 | 0.89 | RORC (0.44) | RORCMRGPRX4MMP8MMP3ADAMTS7 | |
| SCHEMBL4841488 | 0.88 | ALDH1A1 (0.38) | RORCMRGPRX4MMP8MMP3KIFC1 | |
| SCHEMBL4843267 | 0.88 | RORC (0.41) | RORCMMP8MMP3KIFC1 | |
| SCHEMBL4841442 | 0.87 | TRPA1 (0.43) | RORCUSP5MMP8MMP3ADAMTS7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | RORC 1777/4885MRGPRX4 675/4885USP5 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.